			. <u> </u>	
	Application No.	Applicant(s) CARPENTER ET AL.		
Notice of Allemahility	10/645,272			
Notice of Allowability	Examiner	Art Unit		
	D. L. Jones	1618		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.				
1. X This communication is responsive to <u>8/21/03; 11/5/03; and 5/5/05</u> .				
2. The allowed claim(s) is/are 104-156.				
3. The drawings filed on are accepted by the Examiner.				
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 				
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.				
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.				
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.				
(a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached				
1) hereto or 2) to Paper No./Mail Date				
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date				
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).				
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.				
Attachment(s)	5 			
1. Notice of References Cited (PTO-892)	5. Notice of Informal Pa	· · · · · · · · · · · · · · · · · · ·		
 Notice of Draftperson's Patent Drawing Review (PTO-948) MInformation Disclosure Statements (PTO-1449 or PTO/SB/08 	Paper No./Mail Date	 6. ☑ Interview Summary (PTO-413), Paper No./Mail Date <u>5/5/05</u>. 7. ☐ Examiner's Amendment/Comment 		
Paper No./Mail Date 11/5/03	•			
Examiner's Comment Regarding Requirement for Deposit of Richard Meterial	8. 🛛 Examiner's Statemer	nt of Reasons for Allo	wance	
of Biological Material	9. Other			
	o			

Application/Control Number: 10/645,272 Page 2

Art Unit: 1618

CLARIFICATION OF RECORD

1. The previous office action is WITHDRAWN in light of the following action.

Note: The previous office action is being withdrawn because Applicant has submitted an amendment that cancels claims 1-103 over which a restriction requirement was issued.

ACKNOWLEDGMENTS

2. The Examiner acknowledges receipt of the amendment filed 8/21/03 wherein the specification was amended; claims 1-103 were canceled; and claims 104-156 were added.

Note: Claims 104-156 are pending.

ALLOWABLE CLAIMS

3. Claims 104-156 are allowable over the prior art of record. In particular, the claims are distinguished over the prior art because the prior art neither anticipates nor renders obvious the matrix metalloproteinase inhibitor-chelator/surfactant (and optionally, a linking group) conjugate for detecting, imaging, or monitoring congestive heart failure as set forth in independent claims 104 and 136.

COMMENTS/NOTES

4. The lined through documents on the information disclosure statement filed 115/03 were not present in the application during examination. If Applicant would like the documents to be considered, it is respectfully requested that those documents be submitted with the next correspondence to the Examiner.

Application/Control Number: 10/645,272

Art Unit: 1618

Any comments considered necessary by applicant must be submitted no later

Page 3

than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on

Statement of Reasons for Allowance."

6. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to D. L. Jones whose telephone number is (571) 272-0617.

The examiner can normally be reached on Mon.-Fri., 6:45 a.m. - 3:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Thurman Page can be reached on (571) 272-0602. The fax phone number

for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

D. L. Jones

Primary Éxaminer

Art Unit 1616

May 5, 2005